Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market to Experience Robust Growth by 2034 - DelveInsight Analysis | Highlighting Key Players Like GlaxoSmithKline, AstraZeneca, InflaRx

Anti-Neutrophil Cytoplasmic Antibody (ANCA) - Associated Vasculitis emerging therapies, such as Depemokimab, FASENRA, and others, are expected to boost the ANCA-associated vasculitis market in the upcoming years.

DelveInsight has launched a new report on "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the ANCA-associated vasculitis, historical and forecasted epidemiology as well as the ANCA-associated vasculitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Explore more about ANCA-associated vasculitis, treatment options, companies working and therapies: https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report:

In June 2024, the FDA approved a Phase II clinical trial for Ruxoprubart, an investigational therapy targeting ANCA-associated vasculitis. This trial aims to evaluate the efficacy of Ruxoprubart in reducing reliance on high-dose glucocorticoids and minimizing associated toxicities.
In 2023, the total market size for ANCA-associated vasculitis across the 7MM was ~USD 1.5 billion, with strong growth projected due to upcoming therapies like Benralizumab (AstraZeneca) and depemokimab (GlaxoSmithKline).
According to DelveInsight, there were about 215K diagnosed prevalent cases of AAV in the 7MM in 2023, with the US having the highest number of cases, followed by Japan.
Among the subtypes, GPA was the most prevalent. Although MPA has a higher incidence, its prevalence is lower due to more severe initial symptoms and higher mortality.
For relapsing or refractory cases, therapies like rituximab, NUCALA (targeted for GPA/MPA), and TAVNEOS (used in EGPA) offer effective alternatives. TAVNEOS (avacopan) notably gained FDA approval in 2021 as an adjunct treatment for severe GPA and MPA, marking a significant advancement in management.

Due to challenges in timely diagnosis, many patients face delayed treatment, leading to worsened outcomes. This underscores the urgent need for improved early detection methods and reliable biomarkers in managing AAV.
Leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and InflaRx are actively developing new treatments for ANCA-associated vasculitis.
According to DelveInsight's patient-based forecast, NUCALA (mepolizumab) and rituximab held the largest market share among available therapies in the 7MM in 2023.
By 2034, TAVNEOS (avacopan) is expected to lead the market in revenue, potentially exceeding USD 1 billion. Among upcoming therapies, FASENRA (benralizumab) is projected to outperform others like GSK3511294 (depemokimab) in revenue generation.
Key benefits of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market report:
ANCA-associated vasculitis market report covers a descriptive overview and comprehensive insight of the ANCA-associated vasculitis Epidemiology and ANCA-associated vasculitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The ANCA-associated vasculitis market report provides insights into the current and emerging therapies.
The ANCA-associated vasculitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The ANCA-associated vasculitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ANCA-associated vasculitis market.

Got queries? Click here to know more about the ANCA-associated vasculitis market landscape https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Overview

Vasculitides are characterized by inflammation involving leukocytes within blood vessel walls, leading to structural damage. This inflammation can compromise vessel integrity, causing bleeding, narrowing, or blockage of the vessel lumen, which may result in tissue ischemia or necrosis. The size, type, and location of affected vessels vary depending on the specific form of vasculitis. These conditions can occur independently or as a secondary effect of another disease.

ANCA-associated vasculitis refers to a group of rare autoimmune disorders of unknown origin, marked by immune cell infiltration and destruction of small blood vessels. These conditions are typically linked to autoantibodies known as ANCAs, which target neutrophil components. The primary antigens involved are proteinase 3 (PR3) and myeloperoxidase (MPO). The three main types-granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA)-are associated with an immune response against neutrophil granule proteins, primarily PR3 or MPO.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook

Current guidelines for managing ANCA-associated vasculitis focus on halting disease activity, preventing relapse, and managing long-term complications related to tissue damage, medication side effects, and elevated risks of cardiovascular disease and cancer. Most patients begin treatment with induction therapy using cyclophosphamide or rituximab combined with glucocorticoids. This is followed by a maintenance phase using rituximab, azathioprine, or methotrexate, during which glucocorticoids are gradually reduced. While these treatments are generally effective in achieving and sustaining remission, they can come with significant side effects.

Rituximab is frequently preferred for induction due to its effectiveness and favorable safety profile. Common dosing regimens include 375 mg/m2 weekly for four weeks or 1,000 mg administered twice over two weeks. Cyclophosphamide remains a key option, particularly in settings where rituximab is cost-prohibitive. Although the RAVE trial did not provide long-term data on outcomes like cancer or survival, more recent studies indicate that rituximab, unlike cyclophosphamide, does not appear to increase the risk of malignancy.

Explore how the ANCA-associated vasculitis market is rising in the upcoming years @ https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Marketed Drugs
TAVNEOS (avacopan): Chemocentryx/Amgen

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Emerging Drugs

Depemokimab (GSK3511294): GlaxoSmithKline
FASENRA (benralizumab): AstraZeneca

To know more about the therapies that are driving the ANCA-associated vasculitis treatment market, visit: https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key ANCA-associated vasculitis Companies: GlaxoSmithKline, AstraZeneca, InflaRx, and others
Key ANCA-associated vasculitis Therapies: Depemokimab (GSK3511294), FASENRA (benralizumab), TAVNEOS (avacopan), and others
ANCA-associated vasculitis Therapeutic Assessment: ANCA-associated vasculitis current marketed and ANCA-associated vasculitis emerging therapies
ANCA-associated vasculitis Market Dynamics: ANCA-associated vasculitis market drivers and ANCA-associated vasculitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
ANCA-associated vasculitis Unmet Needs, KOL's views, Analyst's views, ANCA-associated vasculitis Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. ANCA-associated vasculitis Patient Share (%) Overview at a Glance
5. ANCA-associated vasculitis Market Overview at a Glance
6. ANCA-associated vasculitis Disease Background and Overview
7. ANCA-associated vasculitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
9. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Current Treatment and Medical Practices
10. Unmet Needs
11. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Emerging Therapies
12. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook
13. Country-Wise Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook 2034 @ https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Pipeline Insights, DelveInsight

"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market. A detailed picture of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis pipeline landscape is provided, including a disease overview and treatment guidelines for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. .

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.